{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T05:21:35Z","timestamp":1788844895364,"version":"build-2803163510"},"reference-count":94,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:00:00Z","timestamp":1768521600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.ejca.2026.116244","type":"journal-article","created":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T16:27:37Z","timestamp":1768580857000},"page":"116244","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Evidence-based AGIHO guideline update on prophylaxis of infectious complications with granulocyte-stimulating factors (G-CSF) for the treatment of adult patients with cancer"],"prefix":"10.1016","volume":"235","author":[{"given":"Michael","family":"Sandherr","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1892-5098","authenticated-orcid":false,"given":"Enrico","family":"Schalk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Werner J.","family":"Heinz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"K\u00f6hler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5259-4651","authenticated-orcid":false,"given":"Stefan W.","family":"Krause","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3551-3450","authenticated-orcid":false,"given":"Blasius","family":"Liss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-7073-5946","authenticated-orcid":false,"given":"Lea","family":"Kausche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9659-0265","authenticated-orcid":false,"given":"Hartmut","family":"Link","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3928-2503","authenticated-orcid":false,"given":"Sibylle C.","family":"Mellinghoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3071-6945","authenticated-orcid":false,"given":"Martin","family":"Schmidt-Hieber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolai","family":"Schuelper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5139-4957","authenticated-orcid":false,"given":"Karsten","family":"Spiekermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2457-6437","authenticated-orcid":false,"given":"Rosanne","family":"Sprute","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7488-4791","authenticated-orcid":false,"given":"Ruth","family":"Seggewiss-Bernhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.ejca.2026.116244_bib1","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1093\/annonc\/mdu035","volume":"25","author":"Vehreschild","year":"2014","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.ejca.2026.116244_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/1469-0691.12037","article-title":"ESCMID* guideline for the diagnosis and management of Candida diseases 2012: developing European guidelines in clinical microbiology and infectious diseases","volume":"18","author":"Ullmann","year":"2012","journal-title":"Clin Microbiol Infect"},{"issue":"3","key":"10.1016\/j.ejca.2026.116244_bib3","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1056\/NEJM199107183250305","article-title":"Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer","volume":"325","author":"Crawford","year":"1991","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ejca.2026.116244_bib4","first-page":"103","volume":"16","author":"Pinter","year":"2017","journal-title":"Clin Colorectal Cancer"},{"key":"10.1016\/j.ejca.2026.116244_bib5","first-page":"05","article-title":"AWMF. Supportive therapie bei onkologischen PatientInnen. Leitlinienprogramm","author":"Deutsche Krebsgesellschaft","year":"2025","journal-title":"Onkol [Dec"},{"issue":"28","key":"10.1016\/j.ejca.2026.116244_bib6","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1200\/JCO.2015.62.3488","article-title":"Recommendations for the Use of WBC growth factors: American society of clinical oncology clinical practice guideline update","volume":"33","author":"Smith","year":"2015","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2026.116244_bib7","doi-asserted-by":"crossref","first-page":"v111","DOI":"10.1093\/annonc\/mdw325","article-title":"Management of febrile neutropaenia: ESMO clinical practice guidelines","volume":"27","author":"Klastersky","year":"2016","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2026.116244_bib8","first-page":"2519","article-title":"Efficacy and safety of lipegfilgrastim versus pegfilgrastim in elderly patients with aggressive B cell non-Hodgkin lymphoma (B-NHL): results of the randomized, open-label, non-inferiority AVOID neutropenia study","volume":"29","author":"Link","year":"2021","journal-title":"Support Care Cancer"},{"issue":"5","key":"10.1016\/j.ejca.2026.116244_bib9","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1002\/ajh.23684","article-title":"A phase III randomized trial of high-dose CEOP + filgrastim versus standard-dose CEOP in patients with non-Hodgkin lymphoma: 10-year follow-up data: Australasian Leukaemia and Lymphoma Group (ALLG) NHL07 trial","volume":"89","author":"Hertzberg","year":"2014","journal-title":"Am J Hematol"},{"issue":"3","key":"10.1016\/j.ejca.2026.116244_bib10","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.7314\/APJCP.2016.17.3.1513","article-title":"Phase III of study of R-CHOP-21 vs R-CHOP-14 for untreated stage III and IV B-cell Non-Hodgkin's lymphoma: a report from Iran","volume":"17","author":"Payandeh","year":"2016","journal-title":"Asian Pac J Cancer Prev"},{"issue":"12","key":"10.1016\/j.ejca.2026.116244_bib11","first-page":"831.e1","article-title":"A Prospective, randomized trial examining the use of G-CSF versus No G-CSF in patients post-autologous transplantation","volume":"28","author":"Grosso","year":"2022","journal-title":"Transpl Cell Ther"},{"issue":"8","key":"10.1016\/j.ejca.2026.116244_bib12","first-page":"4867","article-title":"Outcomes of primary and secondary prophylaxis of chemotherapy-induced and febrile neutropenia in bendamustine plus rituximab regimens in patients with lymphoma and chronic lymphocytic leukemia: real-world, single-center experience","volume":"29","author":"Moore","year":"2021","journal-title":"Support Care Cancer"},{"issue":"5","key":"10.1016\/j.ejca.2026.116244_bib13","first-page":"2309","article-title":"Risk of chemotherapy-induced febrile neutropenia in cancer patients receiving pegfilgrastim prophylaxis: does timing of administration matter?","volume":"24","author":"Weycker","year":"2016","journal-title":"Support Care Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2026.116244_bib14","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3109\/10428194.2011.602771","article-title":"Treatment of Hodgkin lymphoma with adriamycin, bleomycin, vinblastine and dacarbazine without routine granulocyte-colony stimulating factor support does not increase the risk of febrile neutropenia: a prospective cohort study","volume":"53","author":"Minuk","year":"2012","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"10.1016\/j.ejca.2026.116244_bib15","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1080\/10428194.2018.1515939","article-title":"The incidence of bleomycin induced lung toxicity is increased in Hodgkin lymphoma patients over 45 years exposed to granulocyte-colony stimulating growth factor","volume":"60","author":"Andersen","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"10.1016\/j.ejca.2026.116244_bib16","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1093\/annonc\/mdl397","article-title":"ABVD for Hodgkin's lymphoma: full-dose chemotherapy without dose reductions or growth factors","volume":"18","author":"Boleti","year":"2007","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2026.116244_bib17","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1111\/j.1365-2141.2007.06598.x","article-title":"G-CSF is not necessary to maintain over 99% dose-intensity with ABVD in the treatment of Hodgkin lymphoma: low toxicity and excellent outcomes in a 10-year analysis","volume":"137","author":"Evens","year":"2007","journal-title":"Br J Haematol"},{"issue":"8","key":"10.1016\/j.ejca.2026.116244_bib18","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1080\/10428190802210718","article-title":"Isolated neutropenia during ABVD chemotherapy for Hodgkin lymphoma does not require growth factor support","volume":"49","author":"Nangalia","year":"2008","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"10.1016\/j.ejca.2026.116244_bib19","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1056\/NEJMoa1708984","article-title":"Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin's lymphoma","volume":"378","author":"Connors","year":"2018","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ejca.2026.116244_bib20","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1182\/blood.2024024681","article-title":"Brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine for advanced-stage classical Hodgkin lymphoma","volume":"145","author":"Lee","year":"2025","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.ejca.2026.116244_bib21","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1056\/NEJMoa2405888","article-title":"Nivolumab+AVD in advanced-stage classic Hodgkin's lymphoma","volume":"391","author":"Herrera","year":"2024","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.ejca.2026.116244_bib22","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1056\/NEJMoa022473","article-title":"Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease","volume":"348","author":"Diehl","year":"2003","journal-title":"N Engl J Med"},{"issue":"10114","key":"10.1016\/j.ejca.2026.116244_bib23","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1016\/S0140-6736(17)32134-7","article-title":"PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin study group","volume":"390","author":"Borchmann","year":"2017","journal-title":"Lancet"},{"issue":"10450","key":"10.1016\/j.ejca.2026.116244_bib24","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0140-6736(24)01315-1","article-title":"Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial","volume":"404","author":"Borchmann","year":"2024","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.ejca.2026.116244_bib25","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s00277-010-1069-z","article-title":"Myeloid growth factors in acute myeloid leukemia: systematic review of randomized controlled trials","volume":"90","author":"Heuser","year":"2011","journal-title":"Ann Hematol"},{"issue":"6","key":"10.1016\/j.ejca.2026.116244_bib26","article-title":"Colony-stimulating factors for prevention and treatment of infectious complications in patients with acute myelogenous leukemia","volume":"2012","author":"Gurion","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"10","key":"10.1016\/j.ejca.2026.116244_bib27","doi-asserted-by":"crossref","first-page":"E567","DOI":"10.1002\/ajh.24847","article-title":"Intensive consolidation with G-CSF support: Tolerability, safety, reduced hospitalization, and efficacy in acute myeloid leukemia patients \u226560 years","volume":"92","author":"Sperr","year":"2017","journal-title":"Am J Hematol"},{"issue":"5","key":"10.1016\/j.ejca.2026.116244_bib28","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2017.45","article-title":"Condensed versus standard schedule of high-dose cytarabine consolidation therapy with pegfilgrastim growth factor support in acute myeloid leukemia","volume":"7","author":"Jaramillo","year":"2017","journal-title":"Blood Cancer J"},{"issue":"1","key":"10.1016\/j.ejca.2026.116244_bib29","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1200\/JCO.24.00235","article-title":"Single or double induction with 7 + 3 containing standard or high-dose daunorubicin for newly diagnosed AML: the randomized daunodouble trial by the study alliance leukemia","volume":"43","author":"R\u00f6llig","year":"2025","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2026.116244_bib30","doi-asserted-by":"crossref","first-page":"730","DOI":"10.3892\/mco.2015.527","article-title":"Colony-stimulating factors for chemotherapy-related febrile neutropenia are associated with improved prognosis in adult acute lymphoblastic leukemia","volume":"3","author":"Ye","year":"2015","journal-title":"Mol Clin Oncol"},{"issue":"12","key":"10.1016\/j.ejca.2026.116244_bib31","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1093\/annonc\/mdv389","article-title":"A randomised trial of secondary prophylaxis using granulocyte colony-stimulating factor ('SPROG' trial) for maintaining dose intensity of standard adjuvant chemotherapy for breast cancer by the Anglo-Celtic Cooperative Group and NCRN","volume":"26","author":"Leonard","year":"2015","journal-title":"Ann Oncol"},{"issue":"13","key":"10.1016\/j.ejca.2026.116244_bib32","doi-asserted-by":"crossref","first-page":"3024","DOI":"10.1182\/bloodadvances.2020001972","article-title":"DLBCL patients treated with CD19 CAR T cells experience a high burden of organ toxicities but low nonrelapse mortality","volume":"4","author":"Wudhikarn","year":"2020","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.ejca.2026.116244_bib33","doi-asserted-by":"crossref","first-page":"978","DOI":"10.3324\/haematol.2019.238634","article-title":"Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma","volume":"106","author":"Logue","year":"2021","journal-title":"Haematologica"},{"issue":"20","key":"10.1016\/j.ejca.2026.116244_bib34","first-page":"2460","article-title":"How I treat cytopenias after CAR T-cell therapy","volume":"141","author":"Jain","year":"2023","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.ejca.2026.116244_bib35","article-title":"Infections after chimeric antigen receptor (CAR)-T-cell therapy for hematologic malignancies","volume":"25","author":"Kampouri","year":"2023","journal-title":"Transpl Infect Dis"},{"issue":"6","key":"10.1016\/j.ejca.2026.116244_bib36","doi-asserted-by":"crossref","first-page":"e459","DOI":"10.1016\/S2352-3026(24)00077-2","article-title":"Immune effector cell-associated haematotoxicity after CAR T-cell therapy: from mechanism to management","volume":"11","author":"Rejeski","year":"2024","journal-title":"Lancet Haematol"},{"issue":"24","key":"10.1016\/j.ejca.2026.116244_bib37","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1182\/blood.2020010543","article-title":"CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed\/refractory large B-cell lymphoma","volume":"138","author":"Rejeski","year":"2021","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.ejca.2026.116244_bib38","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13045-023-01465-x","article-title":"The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed\/refractory multiple myeloma","volume":"16","author":"Rejeski","year":"2023","journal-title":"J Hematol Oncol"},{"issue":"10","key":"10.1016\/j.ejca.2026.116244_bib39","doi-asserted-by":"crossref","first-page":"E399","DOI":"10.1002\/ajh.26313","article-title":"The impact of granulocyte colony stimulating factor on patients receiving chimeric antigen receptor T-cell therapy","volume":"96","author":"Barreto","year":"2021","journal-title":"Am J Hematol"},{"issue":"3","key":"10.1016\/j.ejca.2026.116244_bib40","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/s41409-021-01526-0","article-title":"Effect of early granulocyte-colony-stimulating factor administration in the prevention of febrile neutropenia and impact on toxicity and efficacy of anti-CD19 CAR-T in patients with relapsed\/refractory B-cell lymphoma","volume":"57","author":"Li\u00e9vin","year":"2022","journal-title":"Bone Marrow Transpl"},{"issue":"10","key":"10.1016\/j.ejca.2026.116244_bib41","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/s41408-022-00741-2","article-title":"Effect of granulocyte colony-stimulating factor on toxicities after CAR T cell therapy for lymphoma and myeloma","volume":"12","author":"Miller","year":"2022","journal-title":"Blood Cancer J"},{"issue":"16","key":"10.1016\/j.ejca.2026.116244_bib42","doi-asserted-by":"crossref","first-page":"4719","DOI":"10.1182\/bloodadvances.2022007776","article-title":"Safety and feasibility of stem cell boost as a salvage therapy for severe hematotoxicity after CD19 CAR T-cell therapy","volume":"6","author":"Rejeski","year":"2022","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.ejca.2026.116244_bib43","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1182\/bloodadvances.2022008042","article-title":"Hematopoietic stem cell boost for persistent neutropenia after CAR T-cell therapy: a GLA\/DRST study","volume":"7","author":"Gagelmann","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.ejca.2026.116244_bib44","article-title":"Impact of granulocyte colony stimulating factor use following CD-19 chimeric antigen receptor T-cell therapy","author":"Winget","year":"2025","journal-title":"Transpl Cell Ther"},{"key":"10.1016\/j.ejca.2026.116244_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2025.102889","article-title":"Diagnosis and management of bispecific T cell-engaging antibody toxicity: a primer for emergency physicians","volume":"134","author":"Wattana","year":"2025","journal-title":"Cancer Treat Rev"},{"issue":"22","key":"10.1016\/j.ejca.2026.116244_bib46","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1056\/NEJMoa2306441","article-title":"Amivantamab plus chemotherapy in NSCLC with EGFR Exon 20 insertions","volume":"389","author":"Zhou","year":"2023","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.ejca.2026.116244_bib47","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1080\/10428194.2019.1576872","article-title":"Blinatumomab versus chemotherapy in first salvage or in later salvage for B-cell precursor acute lymphoblastic leukemia","volume":"60","author":"Dombret","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"12","key":"10.1016\/j.ejca.2026.116244_bib48","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1200\/JCO.22.01725","article-title":"Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell-engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a phase I\/II trial","volume":"41","author":"Thieblemont","year":"2023","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2026.116244_bib49","doi-asserted-by":"crossref","first-page":"e593","DOI":"10.1016\/S2352-3026(24)00166-2","article-title":"Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study","volume":"11","author":"Linton","year":"2024","journal-title":"Lancet Haematol"},{"issue":"24","key":"10.1016\/j.ejca.2026.116244_bib50","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","article-title":"Glofitamab for relapsed or refractory diffuse large B-cell lymphoma","volume":"387","author":"Dickinson","year":"2022","journal-title":"N Engl J Med"},{"issue":"10466","key":"10.1016\/j.ejca.2026.116244_bib51","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(24)01774-4","article-title":"Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial","volume":"404","author":"Abramson","year":"2024","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.ejca.2026.116244_bib52","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1200\/JCO.21.00931","article-title":"Single-agent mosunetuzumab shows durable complete responses in patients with relapsed or refractory B-cell lymphomas: phase I dose-escalation study","volume":"40","author":"Budde","year":"2022","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2026.116244_bib53","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/s41591-023-02726-5","article-title":"Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma: a phase 1b\/2 trial","volume":"30","author":"Budde","year":"2024","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.ejca.2026.116244_bib54","doi-asserted-by":"crossref","first-page":"e327","DOI":"10.1016\/S2352-3026(22)00072-2","article-title":"Odronextamab, a human CD20\u00d7CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial","volume":"9","author":"Bannerji","year":"2022","journal-title":"Lancet Haematol"},{"issue":"16","key":"10.1016\/j.ejca.2026.116244_bib55","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1182\/blood.2023022432","article-title":"Consensus recommendations on the management of toxicity associated with CD3\u00d7CD20 bispecific antibody therapy","volume":"143","author":"Crombie","year":"2024","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.ejca.2026.116244_bib56","doi-asserted-by":"crossref","first-page":"e205","DOI":"10.1016\/S1470-2045(24)00043-3","article-title":"International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma","volume":"25","author":"Rodriguez-Otero","year":"2024","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2026.116244_bib57","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.ejca.2026.116244_bib58","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41408-023-00879-7","article-title":"Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel","volume":"13","author":"Raje","year":"2023","journal-title":"Blood Cancer J"},{"issue":"7","key":"10.1016\/j.ejca.2026.116244_bib59","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1111\/bcp.13586","article-title":"An update on the clinical evidence that supports biosimilar approvals in Europe","volume":"84","author":"Mielke","year":"2018","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.ejca.2026.116244_bib60","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s00228-019-02805-y","article-title":"Clinical evidence supporting the marketing authorization of biosimilars in Europe","volume":"76","author":"Allocati","year":"2020","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.ejca.2026.116244_bib61","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/1745-6215-12-106","article-title":"Through the looking glass: understanding non-inferiority","volume":"12","author":"Schumi","year":"2011","journal-title":"Trials"},{"issue":"9","key":"10.1016\/j.ejca.2026.116244_bib62","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1093\/annonc\/mdx303","article-title":"Pooled analysis of two randomized, double-blind trials comparing proposed biosimilar LA-EP2006 with reference pegfilgrastim in breast cancer","volume":"28","author":"Blackwell","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2026.116244_bib63","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s40164-018-0114-9","volume":"7","author":"Desai","year":"2018","journal-title":"Exp Hematol Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2026.116244_bib64","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s12885-019-5329-6","article-title":"Efficacy and safety of RGB-02, a pegfilgrastim biosimilar to prevent chemotherapy-induced neutropenia: results of a randomized, double-blind phase III clinical study vs. reference pegfilgrastim in patients with breast cancer receiving chemotherapy","volume":"19","author":"Kahan","year":"2019","journal-title":"BMC Cancer"},{"issue":"5","key":"10.1016\/j.ejca.2026.116244_bib65","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1007\/s00277-019-03639-5","article-title":"Randomized phase 3 efficacy and safety trial of proposed pegfilgrastim biosimilar MYL-1401H in the prophylactic treatment of chemotherapy-induced neutropenia","volume":"98","author":"Waller","year":"2019","journal-title":"Ann Hematol"},{"issue":"8","key":"10.1016\/j.ejca.2026.116244_bib66","doi-asserted-by":"crossref","DOI":"10.1200\/GO.21.00276","article-title":"Biosimilar versus originator pegfilgrastim for preventing chemotherapy-induced neutropenia: a phase III randomized, multicenter, evaluator-blinded, noninferiority study","author":"Kowalyszyn","year":"2022","journal-title":"JCO Glob Oncol"},{"issue":"10","key":"10.1016\/j.ejca.2026.116244_bib67","first-page":"976","article-title":"Clinical outcomes of treatment with filgrastim versus a filgrastim biosimilar and febrile neutropenia-associated costs among patients with nonmyeloid cancer undergoing chemotherapy","volume":"24","author":"Schwartzberg","year":"2018","journal-title":"J Manag Care Spec Pharm"},{"issue":"7","key":"10.1016\/j.ejca.2026.116244_bib68","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1007\/s00277-023-05228-z","article-title":"Effectiveness of biosimilar pegfilgrastim in patients with multiple myeloma after high-dose melphalan and autologous stem cell transplantation","volume":"102","author":"Martino","year":"2023","journal-title":"Ann Hematol"},{"key":"10.1016\/j.ejca.2026.116244_bib69","doi-asserted-by":"crossref","DOI":"10.1177\/10781552241290437","article-title":"Real world comparison of filgrastim to filgrastim-sndz in patients with chemotherapy-induced neutropenia","author":"Saad","year":"2024","journal-title":"J Oncol Pharm Pract"},{"issue":"3","key":"10.1016\/j.ejca.2026.116244_bib70","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1007\/s00277-023-05604-9","article-title":"Efficacy and safety of biosimilar Peg-filgrastim after autologous stem cell transplant in myeloma and lymphoma patients: a comparative study with biosimilar Filgrastim, Lenograstim, and originator Peg-filgrastim","volume":"103","author":"Marchesi","year":"2024","journal-title":"Ann Hematol"},{"issue":"10","key":"10.1016\/j.ejca.2026.116244_bib71","doi-asserted-by":"crossref","first-page":"586","DOI":"10.6061\/clinics\/2016(10)06","article-title":"A phase III, randomized, non-inferiority study comparing the efficacy and safety of biosimilar filgrastim versus originator filgrastim for chemotherapy-induced neutropenia in breast cancer patients","volume":"71","author":"Hegg","year":"2016","journal-title":"Clinics"},{"issue":"20","key":"10.1016\/j.ejca.2026.116244_bib72","doi-asserted-by":"crossref","first-page":"20242","DOI":"10.1002\/cam4.6519","article-title":"Efficacy and safety of pegfilgrastim biosimilar MD-110 in patients with breast cancer receiving chemotherapy: single-arm phase III","volume":"12","author":"Takano","year":"2023","journal-title":"Cancer Med"},{"issue":"6","key":"10.1016\/j.ejca.2026.116244_bib73","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1177\/1758834012461330","article-title":"A non-interventional study of biosimilar granulocyte colony-stimulating factor as prophylaxis for chemotherapy-induced neutropenia in a community oncology centre","volume":"4","author":"Verpoort","year":"2012","journal-title":"Ther Adv Med Oncol"},{"issue":"17","key":"10.1016\/j.ejca.2026.116244_bib74","doi-asserted-by":"crossref","first-page":"6102","DOI":"10.1002\/cam4.3261","article-title":"Efficacy and safety of two pegfilgrastim biosimilars: tripegfilgrastim and pegteograstim","volume":"9","author":"Kang","year":"2020","journal-title":"Cancer Med"},{"key":"10.1016\/j.ejca.2026.116244_bib75","doi-asserted-by":"crossref","DOI":"10.2217\/fon-2022-0095","article-title":"Real-world cost-effectiveness of primary prophylaxis with G-CSF biosimilars in patients at intermediate\/high risk of febrile neutropenia","author":"Cornes","year":"2022","journal-title":"Future Oncol"},{"issue":"10","key":"10.1016\/j.ejca.2026.116244_bib76","first-page":"581","article-title":"Cost-effectiveness of granulocyte colony-stimulating factors (G-CSFs) for the prevention of febrile neutropenia (FN) in patients with cancer","volume":"31","author":"Aapro","year":"2023","journal-title":"Support Care Cancer"},{"issue":"12","key":"10.1016\/j.ejca.2026.116244_bib77","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1007\/s40265-023-01911-7","article-title":"Efbemalenograstim alfa: first approval","volume":"83","author":"Blair","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.ejca.2026.116244_bib78","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.addr.2020.07.024","article-title":"Anti-PEG antibodies: properties, formation, testing and role in adverse immune reactions to PEGylated nano-biopharmaceuticals","volume":"154-155","author":"Kozma","year":"2020","journal-title":"Adv Drug Deliv Rev"},{"issue":"23","key":"10.1016\/j.ejca.2026.116244_bib79","doi-asserted-by":"crossref","first-page":"11804","DOI":"10.1021\/acs.analchem.6b03437","article-title":"Analysis of pre-existing IgG and IgM antibodies against polyethylene glycol (PEG) in the general population","volume":"88","author":"Yang","year":"2016","journal-title":"Anal Chem"},{"issue":"2","key":"10.1016\/j.ejca.2026.116244_bib80","first-page":"91","article-title":"Efbemalenograstim alfa not inferior to pegfilgrastim in providing neutrophil support in women with breast cancer undergoing myelotoxic chemotherapy: results of a phase 2 randomized, multicenter, open-label trial","volume":"32","author":"Glaspy","year":"2024","journal-title":"Support Care Cancer"},{"issue":"2","key":"10.1016\/j.ejca.2026.116244_bib81","author":"Glaspy","year":"2025","journal-title":"JCO Oncol Adv"},{"issue":"1","key":"10.1016\/j.ejca.2026.116244_bib82","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1186\/s12885-024-12892-5","article-title":"A randomized, multicenter phase III Study of once-per-cycle administration of efbemalenograstim alfa (F-627), a novel long-acting rhG-CSF, for prophylaxis of chemotherapy-induced neutropenia in patients with breast cancer","volume":"24","author":"Zhang","year":"2024","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2026.116244_bib83","first-page":"34","article-title":"Efbemalenograstim alfa, an Fc fusion protein, long-acting granulocyte-colony stimulating factor for reducing the risk of febrile neutropenia following chemotherapy: results of a phase III trial","volume":"32","author":"Glaspy","year":"2023","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.ejca.2026.116244_bib84","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.breast.2021.03.012","article-title":"A multi-centre study comparing granulocyte-colony stimulating factors to antibiotics for primary prophylaxis of docetaxel-cyclophosphamide induced febrile neutropenia","volume":"58","author":"Clemons","year":"2021","journal-title":"Breast"},{"issue":"4","key":"10.1016\/j.ejca.2026.116244_bib85","doi-asserted-by":"crossref","DOI":"10.1093\/jncics\/pky053","article-title":"Development and validation of a risk score for febrile neutropenia after chemotherapy in patients with cancer: the FENCE score","volume":"2","author":"Aagaard","year":"2018","journal-title":"JNCI Cancer Spectr"},{"issue":"7","key":"10.1016\/j.ejca.2026.116244_bib86","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1182\/blood.2019001272","article-title":"Brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine for nonbulky limited-stage classical Hodgkin lymphoma","volume":"134","author":"Abramson","year":"2019","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.ejca.2026.116244_bib87","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1056\/NEJMoa2206125","article-title":"Overall survival with brentuximab vedotin in stage III or IV Hodgkin's lymphoma","volume":"387","author":"Ansell","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2026.116244_bib88","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1186\/1471-2407-8-195","article-title":"A single dose of pegfilgrastim compared with daily filgrastim for supporting neutrophil recovery in patients treated for low-to-intermediate risk acute myeloid leukemia: results from a randomized, double-blind, phase 2 trial","volume":"8","author":"Sierra","year":"2008","journal-title":"BMC Cancer"},{"issue":"2","key":"10.1016\/j.ejca.2026.116244_bib89","first-page":"119","article-title":"Comparative effectiveness of pegfilgrastim biosimilars vs originator for prevention of febrile neutropenia: a retrospective cohort study","volume":"29","author":"Wang","year":"2023","journal-title":"J Manag Care Spec Pharm"},{"issue":"3","key":"10.1016\/j.ejca.2026.116244_bib90","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.3390\/curroncol29030115","article-title":"The real-world experience of the biosimilar (Grastofil\u00ae) to the reference biologic (Neupogen\u00ae) in breast cancer and lymphoma: a Canadian single-centre retrospective study","volume":"29","author":"Wong","year":"2022","journal-title":"Curr Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2026.116244_bib91","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1177\/1078155220974085","article-title":"A retrospective review of the real-world experience of the Pegfilgrastim biosimilar (Lapelga\u00ae) to the reference biologic (Neulasta\u00ae)","volume":"28","author":"Wong","year":"2022","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.ejca.2026.116244_bib92","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ejca.2017.10.034","article-title":"Comparing granulocyte colony-stimulating factor filgrastim and pegfilgrastim to its biosimilars in terms of efficacy and safety: a meta-analysis of randomised clinical trials in breast cancer patients","volume":"89","author":"Botteri","year":"2018","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.ejca.2026.116244_bib93","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0148901","article-title":"Routine primary prophylaxis for febrile neutropenia with biosimilar granulocyte colony-stimulating factor (Nivestim) or pegfilgrastim is cost effective in Non-Hodgkin lymphoma patients undergoing curative-intent R-CHOP chemotherapy","volume":"11","author":"Wang","year":"2016","journal-title":"PLOS One"},{"issue":"4","key":"10.1016\/j.ejca.2026.116244_bib94","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.clinthera.2015.01.011","article-title":"Potential cost savings from chemotherapy-induced febrile neutropenia with biosimilar filgrastim and expanded access to targeted antineoplastic treatment across the European Union G5 countries: a simulation study","volume":"37","author":"Sun","year":"2015","journal-title":"Clin Ther"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926000249?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926000249?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T09:35:38Z","timestamp":1770716138000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804926000249"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":94,"alternative-id":["S0959804926000249"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116244","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evidence-based AGIHO guideline update on prophylaxis of infectious complications with granulocyte-stimulating factors (G-CSF) for the treatment of adult patients with cancer","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116244","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"116244"}}